Pharmaceutical care program for type 2 diabetes patients in Brazil : a randomised controlled trial.
dc.contributor.author | Mourão, Aline de Oliveira Magalhães | |
dc.contributor.author | Ferreira, Wandiclécia Rodrigues | |
dc.contributor.author | Martins, Maria Auxiliadora Parreiras | |
dc.contributor.author | Reis, Adriano Max Moreira | |
dc.contributor.author | Carrilo, Maria Ruth Gaede Gonçalves | |
dc.contributor.author | Guimarães, Andrea Grabe | |
dc.contributor.author | Ev, Lisiane da Silveira | |
dc.date.accessioned | 2017-02-09T12:13:26Z | |
dc.date.available | 2017-02-09T12:13:26Z | |
dc.date.issued | 2012 | |
dc.description.abstract | Background Brazilians with type 2 diabetes require action to improve haemoglobin A1C levels considering the fact that approximately 73 % of them have poor glycaemic control. Evidence has shown the potential benefits of pharmaceutical care programs in type 2 diabetes patients. Objective To evaluate the effect of a pharmaceutical care program on blood glucose, blood pressure and lipid profile in hyperglycaemic patients undergoing drug treatment for type 2 diabetes. Setting Six primary care units of the Brazilian public health system, Ouro Preto, Brazil. Method An open, randomised, controlled clinical trialwas conducted for 6 months. Subjects aged 18 years or older who were using oral antidiabetic medications and presenting haemoglobin A1C levels C7 % were randomly assigned to receive only usual health care or usual health care plus pharmaceutical intervention. Main outcome measure Haemoglobin A1C. Results A total of 129 subjects were enrolled, and 100 patients completed the study. Compared to the control group (n = 50), the intervention group (n = 50) showed a significant reduction of haemoglobin A1C (-0.6 vs 0.7 %, p = 0.001), fasting plasma glucose, total cholesterol, LDL cholesterol, triglycerides and systolic blood pressure and a significant increase in HDL cholesterol and the use of lipid-modifying agents and platelet aggregation inhibitors. Conclusions This study suggests that a pharmaceutical care program may provide important contributions to reduce haemoglobin A1C in type 2 diabetes patients. Moreover, the promotion of the rational use of drugs may be better achieved in a context of pharmaceutical care programs in Brazil. | pt_BR |
dc.identifier.citation | MOURÃO, A. de O. M. et al. Pharmaceutical care program for type 2 diabetes patients in Brazil : a randomised controlled trial. International Journal of Clinical Pharmacy, v. 35, p.79-86, 2012. Disponível em: <http://link.springer.com/article/10.1007/s11096-012-9710-7>. Acesso em: 10 out. 2016. | pt_BR |
dc.identifier.doi | https://doi.org/10.1007/s11096-012-9710-7 | |
dc.identifier.issn | 2210-7711 | |
dc.identifier.uri | http://www.repositorio.ufop.br/handle/123456789/7238 | |
dc.identifier.uri2 | http://link.springer.com/article/10.1007/s11096-012-9710-7 | pt_BR |
dc.language.iso | en_US | pt_BR |
dc.rights | restrito | pt_BR |
dc.subject | Diabetes mellitus | pt_BR |
dc.subject | Pharmacists | pt_BR |
dc.title | Pharmaceutical care program for type 2 diabetes patients in Brazil : a randomised controlled trial. | pt_BR |
dc.type | Artigo publicado em periodico | pt_BR |